CRYOSTEM develops tailor-made biobanking network solutions for innovative projects and medical research
A collection unique in Europe
Launched within the framework of Investments for the Future by the National Research Agency (ANR), at the heart of the French Government’s Plan Cancer and supported by the National Cancer Institute (INCa), the CRYOSTEM’s project was initiated in 2011 under the auspices of the Francophone Society of Marrow Transplantations and Cellular Therapy (SFGM-TC) to accelerate research in the area of complications of Hematopoietic Stem Cell Transplantation (HSCT), previously called bone marrow transplantation. Today, CRYOSTEM brings together all French transplant units, 28 Biological Resource Centers (BRC) as well as more than 400 French research and healthcare players in the field of severe blood diseases.More
CRYOSTEM network partnering centers
(transplant units and biological resource centers)
Today the CRYOSTEM community offers academic and industrial research teams, a collection of almost 200 000 samples to address life-threatening complications of HSCT.
CRYOSTEM operational project manager
CRYOSTEM is a wonderful opportunity for researchers to better understand the biological mechanisms, to improve the prevention and the management of the complications of HSCT.
Prof. Jean-Hugues Dalle
Department of Pediatric Hematology,
Robert Debré Hospital (AP-HP)
CRYOSTEM could play a significant role to predict the transplant toxicity.
Dr. Boris Calmels
Department of Hematology and Cell Therapy
Founding Member of CRYOSTEM
Throughout the year, CRYOSTEM encourages researchers to apply to gain access to the collection.
Dr. Emilie Robert
CRYOSTEM strategy and development manager
What interests us it is being able to discriminate early before transplantation between patients who are going to benefit from the treatment.
Pr. Régis Peffault de Latour
Department of Hematology,
The Saint Louis Hospital (AP-HP),
Founding Member of CRYOSTEM
of transplanted patients in France
- 5 985 Recipients
- 2 437 Donors
- 17 983 Blood samples
- 48 596 Samples (191 693 aliquots)
- 8 982 Provided aliquots
News & events
CRYOSTEM takes part in the 22nd annual SFGM-TC congressOn this occasion, two posters will be presented on strategies…
Changes within the coordination of the CRYOSTEM networkThe CRYOSTEM coordination team is expanding with the recruitment on…
Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation. Blood
High Predictive Value of the Soluble ZEBRA Antigen (Epstein-Barr Virus Trans-Activator Zta) in Transplant Patients with PTLD. Pathogens
Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures. Science Translational Medicine.
Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. Journal for ImmunoTherapy of Cancer.
Innate lymphoid cell recovery and occurrence of GvHD after hematopoietic stem cell transplantation. J Leukoc Biol.
Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD. Blood Advances.
“CRYOSTEM Biobank: A National Prospective, Standardized Collection to Better Characterize Allogeneic Hematopoietic Stem Cell Transplantation Complications”. Open Journal of Bioresources.
Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. Nature Communications.
CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood.